Alphamab Oncology announced un-audited consolidated earnings result for the six months ended June 30, 2021. For the period, the company reported other income of RMB 22,503,000 compared to RMB 44,341,000 a year ago. Loss for the period was RMB 267,364,000 or RMB 0.29 per basic share compared to RMB 103,100,000 or RMB 0.11 per basic share a year ago.